Should I buy or sell Coherus BioSciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares. View CHRS analyst ratings or view top-rated stocks .

What is Coherus BioSciences' stock price target for 2024?

7 equities research analysts have issued 1 year target prices for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $23.00. On average, they expect the company's share price to reach $11.89 in the next twelve months. This suggests a possible upside of 416.9% from the stock's current price. View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts .

How have CHRS shares performed in 2023?

Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 71.0% and is now trading at $2.30. View the best growth stocks for 2023 here .

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 21,690,000 shares, an increase of 9.3% from the October 31st total of 19,840,000 shares. Based on an average daily volume of 4,280,000 shares, the short-interest ratio is currently 5.1 days. View Coherus BioSciences' Short Interest .

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our CHRS earnings forecast .

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. The biotechnology company earned $74.57 million during the quarter, compared to the consensus estimate of $80.13 million.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) . First Trust Innovation Leaders ETF (ILDR) .

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com . Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO) , Chembio Diagnostics (CEMI) , Exelixis (EXEL) , Heron Therapeutics (HRTX) , TG Therapeutics (TGTX) , Intelsat (I) , Idera Pharmaceuticals (IDRA) , Immunomedics (IMMU) , Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX) .

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Barclays PLC (2.51%), Peregrine Capital Management LLC (1.46%), Northern Trust Corp (0.86%), Rafferty Asset Management LLC (0.79%), Sei Investments Co. (0.75%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Dennis M Lanfear , James Healy , Jean-Frederic Viret, Mcdavid Stilwell , Vincent R Anicetti and Vladimir Vexler . View institutional ownership trends .

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Coherus BioSciences have any subsidiaries?

The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc.. Read More

Coherus BioSciences Stock Price, News & Analysis (NASDAQ:CHRS)

$2.30

0.00 (0.00%)

(As of 12/4/2023 ET)

Compare

Today's Range: $2.21
▼
$2.37
50-Day Range: $1.59
▼
$3.98
52-Week Range: $1.43
▼
$10.99

Volume: 2.84 million shs
Average Volume: 2.80 million shs
Market Capitalization: $256.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.89

Coherus BioSciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 416.9% Upside
$11.89 Price Target
Short Interest: Bearish
19.48% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.08
Upright™ Environmental Score
News Sentiment: 0.08
Based on 7 Articles This Week
Insider Trading: Selling Shares
$450,662 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.17) to ($0.72) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.56 out of 5 stars

Medical Sector

128th out of 952 stocks

Biotechnology Industry

3rd out of 33 stocks

4.4

Analyst's Opinion

Consensus Rating
Coherus BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.89, Coherus BioSciences has a forecasted upside of 416.9% from its current price of $2.30.
Amount of Analyst Coverage
Coherus BioSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
19.48% of the outstanding shares of Coherus BioSciences have been sold short.
Short Interest Ratio / Days to Cover
Coherus BioSciences has a short interest ratio ("days to cover") of 5.1.
Change versus previous month
Short interest in Coherus BioSciences has recently increased by 9.32%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Coherus BioSciences does not currently pay a dividend.
Dividend Growth
Coherus BioSciences does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Coherus BioSciences has received a 69.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Pegfilgrastim", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Coherus BioSciences is -1.08.

2.3

News and Social Media Coverage

News Sentiment
Coherus BioSciences has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Coherus BioSciences this week, compared to 3 articles on an average week.
Search Interest
21 people have searched for CHRS on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Coherus BioSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coherus BioSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,662.00 in company stock.
Percentage Held by Insiders
10.99% of the stock of Coherus BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
91.86% of the stock of Coherus BioSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Coherus BioSciences are expected to grow in the coming year, from ($2.17) to ($0.72) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Coherus BioSciences is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Coherus BioSciences is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Coherus BioSciences Stock (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CHRS Stock News Headlines

November 29, 2023 | markets.businessinsider.com

Buy Rating on Coherus Biosciences Anchored by Competitive Pricing and Market Strategy for Loqtorzi

November 29, 2023 | americanbankingnews.com

Coherus BioSciences (NASDAQ:CHRS) Given Buy Rating at Truist Financial

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 28, 2023 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About Coherus BioSciences

November 28, 2023 | finance.yahoo.com

Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

November 28, 2023 | benzinga.com

Coherus BioSciences Stock (NASDAQ:CHRS) Earnings Dates and Earning Calls

November 26, 2023 | americanbankingnews.com

Dennis M. Lanfear Sells 223,100 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) Stock

November 26, 2023 | americanbankingnews.com

Insider Selling: Coherus BioSciences, Inc. (NASDAQ:CHRS) CEO Sells $450,662.00 in Stock

December 5, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 25, 2023 | morningstar.com

Coherus BioSciences Inc CHRS

November 17, 2023 | msn.com

Baird Initiates Coverage of Coherus Biosciences (CHRS) with Outperform Recommendation

November 17, 2023 | msn.com

Coherus stock rises as Baird initiates coverage on multiple tailwinds

November 15, 2023 | seekingalpha.com

Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval

November 10, 2023 | finance.yahoo.com

Why Coherus BioSciences Was Plummeting This Week

November 9, 2023 | msn.com

Maxim Group Downgrades Coherus Biosciences (CHRS)

November 8, 2023 | seekingalpha.com

Coherus BioSciences Non-GAAP EPS of -$0.27 misses by $0.03, revenue of $74.6M misses by $7.23M

November 7, 2023 | marketwatch.com

Coherus BioSciences Shares Hit All-Time Low

November 7, 2023 | finance.yahoo.com

Coherus BioSciences Inc (CHRS) Reports 27% Rise in Q3 2023 Net Revenue

November 7, 2023 | insidermonkey.com

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Call Transcript

November 7, 2023 | seekingalpha.com

EH, HOWL and TNON among pre-market losers

November 7, 2023 | markets.businessinsider.com

Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket

November 7, 2023 | seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript

November 7, 2023 | msn.com

Coherus stock falls after guidance cut

November 3, 2023 | benzinga.com

Coherus BioSciences's Earnings: A Preview

November 3, 2023 | finance.yahoo.com

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

November 3, 2023 | finance.yahoo.com

Coherus BioSciences to Participate at Upcoming November Investor Conferences

November 1, 2023 | finance.yahoo.com

Vericel Corporation (VCEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

See More Headlines

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CHRS
CUSIP: N/A
CIK: 1512762
Web: www.coherus.com
Phone: (650) 649-3530
Fax: N/A
Employees: 299
Year Founded: 2010

Price Target and Rating

Average Stock Price Target: $11.89
High Stock Price Target: $23.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +416.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.62)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-291,750,000.00
Net Margins: -102.86%
Pretax Margin: -103.04%
Return on Equity: N/A
Return on Assets: -43.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.85
Quick Ratio: 1.58

Sales & Book Value

Annual Sales: $211.04 million
Price / Sales: 1.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.77) per share
Price / Book: -1.30

Miscellaneous

Outstanding Shares: 111,360,000
Free Float: 99,125,000
Market Cap: $256.13 million
Optionable: Optionable
Beta: 0.68

Social Links

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Dennis M. Lanfear (Age 68)
Chairman, President & CEO
Comp: $1.79M
Mr. McDavid Stilwell (Age 51)
Chief Financial Officer
Comp: $719.64k
Mr. Bryan J. Mcmichael (Age 45)
Senior VP of Accounting, Principal Accounting Officer & Corporate Controller
Mr. Richard L. Hameister
Chief Technical Officer
Mr. Marek Ciszewski J.D.
Senior Vice President of Investor Relations
Cheston Turbyfill
Vice President of Communications
Ms. Rebecca Sunshine (Age 60)
Chief Human Resources Officer
Mr. Michael Chen
Senior Vice President of Commercial Analytics & Trade
Mr. Paul Reider (Age 54)
Chief Commercial Officer
Dr. Theresa M. Lavallee Ph.D. (Age 57)
Chief Development Officer & Chairman of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings or view top-rated stocks.
What is Coherus BioSciences' stock price target for 2024?: 7 equities research analysts have issued 1 year target prices for Coherus BioSciences' stock. Their CHRS share price targets range from $6.00 to $23.00. On average, they expect the company's share price to reach $11.89 in the next twelve months. This suggests a possible upside of 416.9% from the stock's current price.
View analysts price targets for CHRS or view top-rated stocks among Wall Street analysts.
How have CHRS shares performed in 2023?: Coherus BioSciences' stock was trading at $7.92 at the start of the year. Since then, CHRS stock has decreased by 71.0% and is now trading at $2.30.
View the best growth stocks for 2023 here.
Are investors shorting Coherus BioSciences?: Coherus BioSciences saw a increase in short interest in November. As of November 15th, there was short interest totaling 21,690,000 shares, an increase of 9.3% from the October 31st total of 19,840,000 shares. Based on an average daily volume of 4,280,000 shares, the short-interest ratio is currently 5.1 days.
View Coherus BioSciences' Short Interest.
When is Coherus BioSciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our CHRS earnings forecast.
How were Coherus BioSciences' earnings last quarter?: Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.07. The biotechnology company earned $74.57 million during the quarter, compared to the consensus estimate of $80.13 million.

What ETFs hold Coherus BioSciences' stock?: ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA).First Trust Innovation Leaders ETF (ILDR).
What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?: 21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Coherus BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).
Who are Coherus BioSciences' major shareholders?: Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Barclays PLC (2.51%), Peregrine Capital Management LLC (1.46%), Northern Trust Corp (0.86%), Rafferty Asset Management LLC (0.79%), Sei Investments Co. (0.75%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends.
How do I buy shares of Coherus BioSciences?: Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Coherus BioSciences have any subsidiaries?: The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More

This page (NASDAQ:CHRS) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial